Pfizer Inc.

NYSE:PFE   9:51:54 AM EDT
-0.10 (-0.20%)

Pfizer Announces Submission Of New Drug Application To The U.S. FDA For Paxlovid

Published: 06/30/2022 10:52 GMT
Pfizer Inc. (PFE) - Pfizer Announces Submission of New Drug Application to the U.S. FDA for Paxlovid.
Pfizer - Submission Seeks Approval for Covid-19 Treatment in Vaccinated & Unvaccinated Individuals at High Risk for Progression to Severe Illness.
Pfizer - NDA Submission Includes Available Safety Data for Paxlovid Generally Consistent in More Than 3,500 Participants Across Epic Clinical Program.
Pfizer - As of End of May 2022, Co Had Shipped More Than 12 Million Treatment Courses of Paxlovid to Nearly 40 Countries.
Pfizer - NDA Submission Includes Data From Epic-hr, Epic-sr and Epic-pep Studies Which Showed Consistent Reduction in Viral Load With Paxlovid.
Pfizer - NDA Submission Includes Data Showing Frequency of Return of Detectable Nasal Viral Rna Following Paxlovid Treatment Was Low.
Further Company Coverage: Pfen ((reuters.